The study, presented at the Society of Interventional Radiology Annual Scientific Meeting, marks one of the first to use freezing on large tumors in the breast.
The FDA-approved technology developed by HeartFlow can predict a patient's long-term risk of target vessel failure as well as more invasive treatments performed inside a cath lab.